Palliative care needs of heart failure patients in China: putting people first

Guo, Ping; Harding, Richard; Higginson, Irene J

doi:10.1097/spc.0000000000000315

Cited by 6 publications

(8 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an emerging health issue, the annual cases of HF are increasing worldwide ( 2 ). In China, a rising prevalence of HF is reported, presenting an economic burden ( 3 ). Clinically, patients with HF show visible symptoms of lethargy, dizziness, and dyspnea, and the risk factors include aging, hypertension, and chronic metabolic disorders ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Bioinformatics and In Silico Findings Uncover Bio-Targets of Calycosin Against Heart Failure and Diabetes Mellitus

Qin

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundHeart failure (HF) and diabetes mellitus (DM) are life-threatening diseases. However, existing clinical drugs to treat HF complicated with DM are relatively limited. In this study, we performed a viable bioinformatics strategy combining network pharmacology and molecular docking to identify potential anti-HF and -DM targets and therapeutic mechanisms of calycosin, a functional phytoestrogen.MethodsWeb-based databases were used to collect candidate genes/targets of calycosin and HF/DM and then identify the hub bio-targets of calycosin against HF/DM. Using the online-available database, all functional processes and signaling pathways of calycosin against HF/DM were screened and identified before further visualization.ResultsAll potential bio-targets of calycosin and HF/DM were collected, and 20 hub targets of calycosin against HF/DM were identified. Interestingly, molecular docking findings indicated that mitogen-activated protein kinase-1 (MAPK1), β-arrestin 1 (ARRB1), and homologue-1 (ABL1) may be potent pharmacological targets of calycosin against HF/DM. In addition, all primary molecular functions of calycosin against HF/DM were identified, including regulating protein binding, ubiquitination, and the metabolic process. Furthermore, the top molecular pathways of calycosin against HF/DM were revealed, including cardiomyocyte and chemokine signaling pathways.ConclusionOur bioinformatics analysis uncovered the network targets and therapeutic mechanisms of calycosin against HF/DM. For the first time, the current in silico findings revealed that the identified hub targets may be used to screen and treat HF/DM.

show abstract

Section: Introductionmentioning

confidence: 99%

Bioinformatics and In Silico Findings Uncover Bio-Targets of Calycosin Against Heart Failure and Diabetes Mellitus

Qin

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…The incidence rate of cancer is more than one-third worldwide, and cardiovascular disease is the two causes of death in developed countries. Doxorubicin (DOX), a cardiotoxic anthracycline chemotherapy drug, was first isolated from Streptomyces peucetius caesius in 1967 [ 1 , 2 ]. DOX plays an important role in the treatment of many cancers, as 32% of patients with breast cancer, 57-70% of elderly patients with lymphoma, and 50-60% of children with cancer have been treated with anthracycline drugs [ 3 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

Orosomucoid 1 Attenuates Doxorubicin‐Induced Oxidative Stress and Apoptosis in Cardiomyocytes via Nrf2 Signaling

Cheng

Liú

Xing

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Doxorubicin (DOX) is an effective anticancer drug, but its therapeutic use is limited by its cardiotoxicity. The principal mechanisms of DOX-induced cardiotoxicity are oxidative stress and apoptosis in cardiomyocytes. Orosomucoid 1 (ORM1), an acute-phase protein, plays important roles in inflammation and ischemic stroke; however, the roles and mechanisms of ORM1 in DOX-induced cardiotoxicity remain unknown. Therefore, in the present study, we aimed to investigate the function of ORM1 in cardiomyocytes experiencing DOX-induced oxidative stress and apoptosis. A DOX-induced cardiotoxicity animal model was established in C57BL/6 mice by administering an intraperitoneal injection of DOX (20 mg/kg), and the control group was intraperitoneally injected with the same volume of sterilized saline. The effects were assessed after 7 d. Additionally, H9c2 cells were stimulated with DOX (10 μM) for 24 h. The results showed decreased ORM1 and increased oxidative stress and apoptosis after DOX stimulation in vivo and in vitro. ORM1 overexpression significantly reduced DOX-induced oxidative stress and apoptosis in H9c2 cells. ORM1 significantly increased the expression of nuclear factor-like 2 (Nrf2) and its downstream protein heme oxygenase 1 (HO-1) and reduced the expression of the lipid peroxidation end product 4-hydroxynonenal (4-HNE) and the level of cleaved caspase-3. In addition, Nrf2 silencing reversed the effects of ORM1 on DOX-induced oxidative stress and apoptosis in cardiomyocytes. In conclusion, ORM1 inhibited DOX-induced oxidative stress and apoptosis in cardiomyocytes by regulating the Nrf2/HO-1 pathway, which might provide a new treatment strategy for DOX-induced cardiotoxicity.

show abstract

“…To provide care which is tailored to the individual, the literature recommends that patients and health care professionals understand and assess symptoms [44] and patient and families should understand the illness trajectory [45]. Knowledge of which treatments and palliative interventions are effective for symptom burden is crucial [4,42,43,46], including treatments for fatigue [47], and the use of opioids in CHF [48].…”

Section: Clinicalmentioning

confidence: 99%

“…An important element of integrated palliative care in CHF care is identifying which patients with CHF would benefit from specific palliative care interventions [30,45,68] especially earlier in the illness trajectory [54]. Integrated palliative care is facilitated by assessing the impact of palliative care interventions on patient-reported outcome measures [43] such as the Integrated Palliative Care Outcomes Scale [44,69], quality of life measures [56,70], the impact on mortality, caregiver burden [34] and patient and family satisfaction [42].…”

Section: Clinicalmentioning

confidence: 99%

Elements of Integrated Palliative Care in Chronic Heart Failure Across the Care Continuum: A Scoping Review

Singh¹,

Ivynian²,

Davidson³

et al. 2022

Heart, Lung and Circulation

View full text Add to dashboard Cite

Palliative care needs of heart failure patients in China: putting people first

Abstract: Large-scale epidemiological studies are urgently needed to assess the current situation of heart failure in China, alongside interventional studies to drive the development of innovative palliative care services to address the needs of Chinese heart failure patients.

Cited by 6 publications

References 55 publications

Bioinformatics and In Silico Findings Uncover Bio-Targets of Calycosin Against Heart Failure and Diabetes Mellitus

Bioinformatics and In Silico Findings Uncover Bio-Targets of Calycosin Against Heart Failure and Diabetes Mellitus

Orosomucoid 1 Attenuates Doxorubicin‐Induced Oxidative Stress and Apoptosis in Cardiomyocytes via Nrf2 Signaling

Elements of Integrated Palliative Care in Chronic Heart Failure Across the Care Continuum: A Scoping Review

Contact Info

Product

Resources

About